5-α-reductase Inhibitor Articles

To investigate the efficacy and safety of various medical treatment schemes in the management of patients at high risk of progression of benign prostatic hyperplasia (BPH), depending on concomitant erectile dysfunction (ED).

Purpose: This study aimed to investigate the effect of androgen suppression therapy (AST), comprising a 5-α reductase inhibitor (5-ARi) and androgen deprivation therapy (ADT), on the risk of bladder cancer incidence, recurrence, and mortality.

BERKELEY, CA (UroToday.com) - Our initial study “Finasteride Use in the Male Infertility Population: Effects on Semen and Hormonal Parameters”, was published in Fertility and Sterility in 2013. In this study, we found that finasteride, even at low doses, caused reduced sperm counts in some infertile men. While only 27 men were taking finasteride in our cohort, sperm counts improved dramatically (mean 11.6 fold increase) following finasteride discontinuation.

Sexual dysfunction is a common side effect of medical therapy for benign prostatic hyperplasia (BPH), whereas prostatic urethral lift (PUL) offers safe and effective relief of lower urinary tract symptoms while preserving sexual function.

To describe the real-world therapeutic management of patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) (LUTS/BPH) attending primary care and urology clinics in Spain.

BERKELEY, CA (UroToday.com) - Urinary retention (UR) is one of the most usual and significant complications of long-term BPH. The risk is cumulative and increases with age. Moreover, recurrent urinary retention in elderly often indicates a poor detrusor function, which represents a risk factor of both surgical and conservative therapy failure.